查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600140

男性不孕症市场：按测试、治疗类型和最终用户划分 - 2025-2030 年全球预测

Male Infertility Market by Test (Computer-Assisted Semen Analysis, DNA Fragmentation Technique, Microscopic Examination), Treatment Type (Assisted Reproductive Technologies & Surgery, Medication), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年男性不孕症市场价值为37.7亿美元，预计2024年将达到40.9亿美元，复合年增长率为8.94%，到2030年将达到68.8亿美元。

男性不孕症市场的范围包括旨在解决男性生殖问题因素的各种诊断和治疗程序。男性不孕症被定义为无法在有生育能力的女性伴侣中诱导怀孕，主要是由于精子产量低、精子功能异常或精子输送受阻。由于年龄、生活方式因素和环境暴露，全球范围内不孕症的盛行率日益增加，因此需要解决男性不孕症问题。应用范围从精液分析和荷尔蒙评估等诊断测试到药物、手术和辅助生殖技术 (ART) 等治疗，包括体外受精 (IVF) 和显微授精 (ICSI)。最终用途包括医疗保健提供者、生育诊所和研究机构，以从诊断工具和治疗性介入的进步中受益。

主要市场统计
基准年[2023] 37.7亿美元
预测年份 [2024] 40.9亿美元
预测年份 [2030] 68.8亿美元
复合年增长率（%） 8.94%

根据市场洞察，人们对不孕症治疗的认识和社会接受度的提高正在增加对男性不孕症治疗的需求。影响成长的关键因素包括诊断平台的技术创新和抗逆转录病毒疗法的广泛应用。个人化医疗方法存在潜在的治疗机会，可以根据基因图谱优化治疗计划并提高成功率。然而，它面临着高昂的治疗费用、有限的保险范围以及与男性不孕症相关的社会文化耻辱等挑战，这可能会阻碍市场的成长。创新可能会在非侵入性诊断技术的开发和针对特定分子途径的新药的寻找中得到发展。此外，整合数位健康平台可以简化流程并提高病人参与。

男性不孕症市场正在演变成一个技术主导的领域，为研究主导的公司引入尖端解决方案提供了巨大的机会。投资于教育宣传活动以减少男性不孕症的耻辱和降低成本障碍的技术的公司将能够占领重要的市场占有率。解决这些限制，特别是透过与医疗保健支付者和倡导团体建立策略伙伴关係，可以促进市场扩张并促进创新。

市场动态：揭示快速发展的男性不孕症市场的关键市场洞察

供需的动态交互作用正在改变男性不孕市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 提高对男性不孕症的认识与教育
    • 由于生活型态相关因素，男性不孕症盛行率增加
    • 透过改善男性不孕症诊断和治疗服务的机会来扩大医疗基础设施
  • 市场限制因素
    • 男性不孕症治疗高成本
  • 市场机会
    • 透过量身定制的治疗实现个人化医疗的趋势日益增强
    • 基因编辑技术的进步
  • 市场问题
    • 男性不孕症治疗保险范围的限制

波特五力：驾驭男性不孕症市场的策略工具

波特的五力架构是了解男性不孕症市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解男性不孕症市场的外部影响

外部宏观环境因素在塑造男性不孕症市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解男性不孕症市场的竞争格局

男性不孕症市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：男性不孕症市场供应商绩效评估

FPNV定位矩阵是评估男性不孕症市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製男性不孕症市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，男性不孕症市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 提高对男性不孕症的认识与教育
      • 由于生活型态相关因素，男性不孕症盛行率增加
      • 扩大医疗基础设施并改善男性不孕症诊断和治疗服务的可近性
    • 抑制因素
      • 男性不孕症治疗费用高昂
    • 机会
      • 透过客製化治疗计划实现个人化医疗的趋势正在扩大。
      • 基因编辑技术的进步
    • 任务
      • 男性不孕症治疗的保险范围有限。
  • 市场区隔分析
    • 检测：全面且准确的评估增加了电脑辅助精液分析的应用
    • 最终用户：专业化和专业知识将增加生育中心男性不孕症检测的采用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 男性不孕市场：通过测试

  • 介绍
  • 电脑辅助精液分析
  • DNA分割技术
  • 显微镜检查
  • 氧化压力分析
  • 精子聚集
  • 精子穿透试验

第七章男性不孕市场：依治疗类型

  • 介绍
  • 辅助生殖技术与手术
  • 药物治疗

第八章 男性不孕市场：依最终用户分类

  • 介绍
  • 不孕不孕治疗中心
  • 医院/诊所
  • 研究所

第九章美洲男性不孕市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太男性不孕市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲男性不孕症市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Birla Fertility & IVF 收购 ARMC IVF，以提高不孕症治疗的可近性和品质
    • Maven Clinic 透过新的男性不孕症支持和扩大的虚拟护理来促进生育计划
    • 那格浦尔 ICMR 开发突破性套件来识别男性不孕症的遗传原因
  • 战略分析和建议

公司名单

  • Aarti Medicals Pvt. Ltd.
  • Adorefem
  • Andrology Solutions
  • Bayer AG
  • CinnaGen Co.
  • Cipla Limited
  • Dallas IVF
  • Ferring Global
  • Gladfem by Zoic Group
  • Glenmark Pharmaceuticals Limited
  • HCA International Limited
  • Intas Pharmaceuticals Ltd.
  • Male Fertility & Sexual Medicine Specialists
  • Maze Laboratories
  • Merck KGaA
  • Midwest Fertility Specialists
  • NTMIC Sperm Lab
  • Oasis Fertility
  • SCSA Diagnostics, Inc.
  • Shady Grove Fertility
  • Sun Pharmaceutical Industries Limited
  • Theramex
  • Vitrolife Sweden AB
  • Winfertility
  • Zydus Lifesciences Limited
Product Code: MRR-43286DA08074

The Male Infertility Market was valued at USD 3.77 billion in 2023, expected to reach USD 4.09 billion in 2024, and is projected to grow at a CAGR of 8.94%, to USD 6.88 billion by 2030.

The scope of the male infertility market encompasses various diagnostic and treatment procedures designed to address factors contributing to male reproductive issues. Male infertility is defined as the inability to cause pregnancy in a fertile female partner, primarily due to low sperm production, abnormal sperm function, or blockages that prevent sperm delivery. The necessity of addressing male infertility arises from the increasing prevalence of infertility cases globally, driven by age, lifestyle factors, and environmental exposures. Its applications range from diagnostic testing, such as semen analysis and hormonal evaluations, to treatments like medication, surgery, and assisted reproductive technologies (ART) including in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). The end-use scope extends to healthcare providers, fertility clinics, and research institutions, which benefit from advancements in diagnostic tools and therapeutic interventions.

KEY MARKET STATISTICS
Base Year [2023] USD 3.77 billion
Estimated Year [2024] USD 4.09 billion
Forecast Year [2030] USD 6.88 billion
CAGR (%) 8.94%

Market insights reveal a growing demand for male infertility treatments attributed to increased awareness and societal acceptance of fertility health. Key factors influencing growth include technological innovations in diagnostic platforms and the broader availability of ARTs. There exists potential opportunities in personalized medicine approaches, which can optimize treatment plans based on genetic profiling, improving success rates. However, the market faces challenges such as high treatment costs, limited insurance coverage, and the socio-cultural stigmatization associated with male infertility, which may impede growth. Innovation can thrive in the development of non-invasive diagnostic techniques and the exploration of novel pharmaceuticals targeting specific molecular pathways. Furthermore, integrating digital health platforms could streamline processes and enhance patient engagement.

The male infertility market is evolving into a technologically-driven domain that provides a significant opportunity for research-driven companies to introduce cutting-edge solutions. Companies that invest in educational campaigns to destigmatize male infertility and in technologies that reduce cost barriers will be well-positioned to capture a substantial market share. Addressing these limitations, particularly by forming strategic partnerships with healthcare payers and advocacy groups, can catalyze market expansion and foster innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Male Infertility Market

The Male Infertility Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing awareness and education about male infertility
    • Increased prevalence of male infertility cases due to lifestyle-related factors
    • Expanding healthcare infrastructure with enhanced accessibility to male infertility diagnostic and treatment services
  • Market Restraints
    • High costs associated with male infertility treatments
  • Market Opportunities
    • Growing trend of personalized medicine with tailored treatment plans
    • Technological advancements in gene-editing
  • Market Challenges
    • Limited insurance coverage for male infertility treatments

Porter's Five Forces: A Strategic Tool for Navigating the Male Infertility Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Male Infertility Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Male Infertility Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Male Infertility Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Male Infertility Market

A detailed market share analysis in the Male Infertility Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Male Infertility Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Male Infertility Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Male Infertility Market

A strategic analysis of the Male Infertility Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Male Infertility Market, highlighting leading vendors and their innovative profiles. These include Aarti Medicals Pvt. Ltd., Adorefem, Andrology Solutions, Bayer AG, CinnaGen Co., Cipla Limited, Dallas IVF, Ferring Global, Gladfem by Zoic Group, Glenmark Pharmaceuticals Limited, HCA International Limited, Intas Pharmaceuticals Ltd., Male Fertility & Sexual Medicine Specialists, Maze Laboratories, Merck KGaA, Midwest Fertility Specialists, NTMIC Sperm Lab, Oasis Fertility, SCSA Diagnostics, Inc., Shady Grove Fertility, Sun Pharmaceutical Industries Limited, Theramex, Vitrolife Sweden AB, Winfertility, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Male Infertility Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test, market is studied across Computer-Assisted Semen Analysis, DNA Fragmentation Technique, Microscopic Examination, Oxidative Stress Analysis, Sperm Agglutination, and Sperm Penetration Assay.
  • Based on Treatment Type, market is studied across Assisted Reproductive Technologies & Surgery and Medication.
  • Based on End User, market is studied across Fertility Centers, Hospitals & Clinics, and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing awareness and education about male infertility
      • 5.1.1.2. Increased prevalence of male infertility cases due to lifestyle-related factors
      • 5.1.1.3. Expanding healthcare infrastructure with enhanced accessibility to male infertility diagnostic and treatment services
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with male infertility treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing trend of personalized medicine with tailored treatment plans
      • 5.1.3.2. Technological advancements in gene-editing
    • 5.1.4. Challenges
      • 5.1.4.1. Limited insurance coverage for male infertility treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Test: Rising application of computer-assisted semen analysis owing to comprehensive and accurate assessments
    • 5.2.2. End User: Increasing incorporation of male fertility tests in fertility centers due to specialization and expertise
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Male Infertility Market, by Test

  • 6.1. Introduction
  • 6.2. Computer-Assisted Semen Analysis
  • 6.3. DNA Fragmentation Technique
  • 6.4. Microscopic Examination
  • 6.5. Oxidative Stress Analysis
  • 6.6. Sperm Agglutination
  • 6.7. Sperm Penetration Assay

7. Male Infertility Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Assisted Reproductive Technologies & Surgery
  • 7.3. Medication

8. Male Infertility Market, by End User

  • 8.1. Introduction
  • 8.2. Fertility Centers
  • 8.3. Hospitals & Clinics
  • 8.4. Research Institutes

9. Americas Male Infertility Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Male Infertility Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Male Infertility Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Birla Fertility & IVF Acquires ARMC IVF to Improve Accessibility and Quality of Infertility Treatment
    • 12.3.2. Maven Clinic Enhances Fertility Program with New Male Infertility Support and Expanded Virtual Care
    • 12.3.3. ICMR Nagpur Develops Breakthrough Kit to Identify Genetic Causes of Male Infertility
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aarti Medicals Pvt. Ltd.
  • 2. Adorefem
  • 3. Andrology Solutions
  • 4. Bayer AG
  • 5. CinnaGen Co.
  • 6. Cipla Limited
  • 7. Dallas IVF
  • 8. Ferring Global
  • 9. Gladfem by Zoic Group
  • 10. Glenmark Pharmaceuticals Limited
  • 11. HCA International Limited
  • 12. Intas Pharmaceuticals Ltd.
  • 13. Male Fertility & Sexual Medicine Specialists
  • 14. Maze Laboratories
  • 15. Merck KGaA
  • 16. Midwest Fertility Specialists
  • 17. NTMIC Sperm Lab
  • 18. Oasis Fertility
  • 19. SCSA Diagnostics, Inc.
  • 20. Shady Grove Fertility
  • 21. Sun Pharmaceutical Industries Limited
  • 22. Theramex
  • 23. Vitrolife Sweden AB
  • 24. Winfertility
  • 25. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. MALE INFERTILITY MARKET RESEARCH PROCESS
  • FIGURE 2. MALE INFERTILITY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MALE INFERTILITY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MALE INFERTILITY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MALE INFERTILITY MARKET SIZE, BY TEST, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MALE INFERTILITY MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES MALE INFERTILITY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES MALE INFERTILITY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. MALE INFERTILITY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. MALE INFERTILITY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MALE INFERTILITY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MALE INFERTILITY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MALE INFERTILITY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MALE INFERTILITY MARKET DYNAMICS
  • TABLE 7. GLOBAL MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MALE INFERTILITY MARKET SIZE, BY COMPUTER-ASSISTED SEMEN ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MALE INFERTILITY MARKET SIZE, BY DNA FRAGMENTATION TECHNIQUE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPIC EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MALE INFERTILITY MARKET SIZE, BY OXIDATIVE STRESS ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MALE INFERTILITY MARKET SIZE, BY SPERM AGGLUTINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MALE INFERTILITY MARKET SIZE, BY SPERM PENETRATION ASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGIES & SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES MALE INFERTILITY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. MALE INFERTILITY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. MALE INFERTILITY MARKET, FPNV POSITIONING MATRIX, 2023